Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
What side effects of CAR T therapies are currently known?
Primary side effects of CAR T therapies occur early on after treatment and they’re related to the growth of the T cells and the actual activity of the T cells. So many patients will have fever and potentially progressing to more serious symptoms requiring hospital-level care and sometimes ICU-level care. Those symptoms typically resolve within the first week or sometimes within the first several weeks.
The main side effects of this therapy are within the first 28 days. But there’s lots of monitoring and potential for long-term side effects as well. Most patients are usually physically very well after the first month of treatment, but still require some focused monitoring for some of the on-target effects of CAR T cells, which involve B-cell aplasia. So, these patients, because of how CD19 CAR T cells work, will be depleted of their normal B cells, and that requires monitoring and replacement of the immunoglobulin long term.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More